

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1745 Selected Articles from This Issue

MCT FIRST DISCLOSURES

- 1747 BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors**
Michael Rigby, Gavin Bennett, Lihong Chen, Gemma E. Mudd, Helen Harrison, Paul J. Beswick, Katherine Van Rietschoten, Sophie M. Watcham, Heather S. Scott, Amy N. Brown, Peter U. Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J. Skynner, Phil Jeffrey, Nicholas Keen, and Kevin Lee

REVIEW

- 1757 JAK: Not Just Another Kinase**
Ruchi P. Agashe, Scott M. Lippman, and Razelle Kurzrock

SMALL MOLECULE THERAPEUTICS

- 1765 First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis**
Mari Karimaa, Reetta Riikonen, Henna Kettunen, Päivi Taavitsainen, Meri Ramela, Marcin Chrusciel, Stefan Karlsson, Petteri Rummakko, Outi Simola, Gerd Wohlfahrt, Pasi Hakulinen, Annamari Vuorela, Heikki Joensuu, Tapio Utriainen, Karim Fizazi, and Riikka Oksala
- 1777 Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/ β -Catenin Signaling in BRAF-mutant Colorectal Cancer Models**
Khanh B. Tran, Sharada Kolekar, Qian Wang, Jen-Hsing Shih, Christina M. Buchanan, Sanjeev Deva, and Peter R. Shepherd
- 1788 Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models**
Didier Scherrer, Noel Barrett, Luc Teyton, Tillman Pearce, Josianne Nitcheu, Philippe Pouletty, Julien Santo, and Hartmut J. Ehrlich

1798 Inhibition of NF- κ B DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation

Manpreet Bariana, Elena Cassella, Janice Rateshwar, Samedy Ouk, Hsiou-Chi Liou, Claudia Heller, Iriana Colorado, Rena Feinman, Ali Makhdoom, David S. Siegel, Glenn Heller, Andrea Tuckett, Patrizia Mondello, and Johannes L. Zakrzewski

- 1810 IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression**
Jonathan J. Hue, Hallie J. Graor, Mehrdad Zarei, Erryk S. Katayama, Karen Ji, Omid Hajihassani, Alexander W. Loftus, Ali Vaziri-Gohar, and Jordan M. Winter

- 1823 Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors**
Christine Helsen, Tien T. Nguyen, Xiao Yin Lee, Roy Eerlings, Nikolaos Louros, Joost Schymkowitz, Frederic Rousseau, Frank Claessens, and Arnout Voet

LARGE MOLECULE THERAPEUTICS

- 1835 Preclinical Evaluation of ^{225}Ac -Labeled Single-Domain Antibody for the Treatment of HER2^{pos} Cancer**
Magdalena Rodak, Yana Dekempeneer, Maria Wojewódzka, Vicky Caveliers, Peter Covens, Brian W. Miller, Matthijs B. Sevenois, Frank Bruchertseifer, Alfred Morgenstern, Tony Lahoutte, Matthias D'Huyvetter, and Marek Pruszyński
- 1846 Computational Modeling of TP63-TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics**
E. Sila Ozdemir, Michelle M. Gomes, and Jared M. Fischer

TABLE OF CONTENTS

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1857 External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

Umang Swami, Nicolas Sayegh, Yeonjung Jo,
Benjamin Haaland, Taylor Ryan McFarland,
Roberto H. Nussenzeveig, Divyam Goel, Deepika Sirohi,
Andrew W. Hahn, Benjamin L. Maughan,
Amir Goldkorn, and Neeraj Agarwal

TARGETING DRUG RESISTANCE

1862 NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Marta Llaurodo Fernandez, E. Marielle Hijmans,
Annemiek M.C. Gennissen, Nelson K.Y. Wong,
Shang Li, G. Bea A. Wisman, Aleksandra Hamilton,
Joshua Hoenisch, Amy Dawson, Cheng-Han Lee,
Madison Bittner, Hannah Kim, Gabriel E. DiMattia,
Christianne A.R. Lok, Cor Liefink,
Roderick L. Beijersbergen, Steven de Jong,
Mark S. Carey, René Bernards, and Katrien Berns

ABOUT THE COVER

Bicycles binding Nectin-4 are selected by phage display and subsequently chemically optimised. Conjugation to the toxin through a spacer and cleavable linker generates the *Bicycle* Toxin Conjugate (BTC™) BT8009 with a Bicycle Toxin Ratio of 1. The small size of BT8009 leads to fast extravasation and excellent tumor penetration, resulting in rapid regression of target expressing large and small tumors of several types (shown are lung and head and neck PDX models). Efficacy was comparable or superior to a Nectin-4 ADC. Image created with BioRender.com. Read the full article on page 1747.

doi: 10.1158/1535-7163.MCT-21-12-CVR

